Target Information

Target General Infomation
Target ID
T78890
Former ID
TTDI02330
Target Name
Tissue factor pathway inhibitor
Gene Name
TFPI
Synonyms
EPI; Extrinsic pathway inhibitor; LACI; Lipoprotein-associated coagulation inhibitor; TFPI
Target Type
Clinical Trial
Disease Factor IX deficiency [ICD10: D67]
Sepsis [ICD9: 995.91; ICD10: A40, A41]
Function
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.
UniProt ID
P10646
Sequence
MIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADD
GPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQE
KPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPN
GFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIG
KCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIF
VKNM
Drugs and Mode of Action
Drug(s) Tifacogin Drug Info Phase 3 Sepsis [526665]
BAX-499 Drug Info Phase 1 Factor IX deficiency [523151]
NN-7415 Drug Info Phase 1 Factor IX deficiency [523229]
Inhibitor BAX-499 Drug Info [531922], [532285]
Tifacogin Drug Info [526665]
Modulator NN-7415 Drug Info
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Complement and coagulation cascades
NetPath Pathway IL4 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Blood coagulation
Pathway Interaction Database Syndecan-4-mediated signaling events
Reactome Extrinsic Pathway of Fibrin Clot Formation
WikiPathways Complement and Coagulation Cascades
Integrated Breast Cancer Pathway
Formation of Fibrin Clot (Clotting Cascade)
References
Ref 523151ClinicalTrials.gov (NCT01191372) First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients. U.S. National Institutes of Health.
Ref 523229ClinicalTrials.gov (NCT01228669) Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B. U.S. National Institutes of Health.
Ref 526665Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
Ref 526665Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
Ref 531922Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost. 2012 Aug;10(8):1581-90.
Ref 532285Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.